See more : Tikun Olam-Cannbit Pharmaceuticals Ltd (TKUN.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Kyverna Therapeutics, Inc. (KYTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyverna Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- GreenVision Acquisition Corp. (GRNVU) Income Statement Analysis – Financial Results
- PesoRama Inc. (PESO.V) Income Statement Analysis – Financial Results
- Great Dane Europa Value (GDIEUV.CO) Income Statement Analysis – Financial Results
- Shree Pushkar Chemicals & Fertilisers Limited (SHREEPUSHK.NS) Income Statement Analysis – Financial Results
- Tah Hsin Industrial Corporation (1315.TW) Income Statement Analysis – Financial Results
Kyverna Therapeutics, Inc. (KYTX)
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 0.00 | 7.03M | 5.66M |
| Cost of Revenue | 1.71M | 1.05M | 586.00K |
| Gross Profit | -1.71M | 5.97M | 5.07M |
| Gross Profit Ratio | 0.00% | 85.04% | 89.64% |
| Research & Development | 49.92M | 28.40M | 25.85M |
| General & Administrative | 12.48M | 8.01M | 6.15M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 12.48M | 8.01M | 6.15M |
| Other Expenses | 0.00 | -9.00K | -2.00K |
| Operating Expenses | 62.41M | 36.41M | 32.00M |
| Cost & Expenses | 62.41M | 36.41M | 32.00M |
| Interest Income | 2.28M | 565.00K | 1.00K |
| Interest Expense | 187.00K | 65.00K | 3.00K |
| Depreciation & Amortization | 1.71M | 1.05M | 586.00K |
| EBITDA | -58.47M | -27.78M | -25.76M |
| EBITDA Ratio | 0.00% | -395.40% | -455.46% |
| Operating Income | -62.41M | -29.38M | -26.35M |
| Operating Income Ratio | 0.00% | -418.28% | -465.81% |
| Total Other Income/Expenses | 2.04M | 491.00K | -4.00K |
| Income Before Tax | -60.37M | -28.89M | -26.35M |
| Income Before Tax Ratio | 0.00% | -411.29% | -465.88% |
| Income Tax Expense | 0.00 | 56.00K | 1.00K |
| Net Income | -60.37M | -28.89M | -26.35M |
| Net Income Ratio | 0.00% | -411.29% | -465.88% |
| EPS | 0.00 | -1.12 | -1.02 |
| EPS Diluted | 0.00 | -1.12 | -1.02 |
| Weighted Avg Shares Out | 673.62M | 25.80M | 25.80M |
| Weighted Avg Shares Out (Dil) | 673.62M | 25.80M | 25.80M |
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Kyverna Therapeutics Announces Leadership Update
Kyverna Therapeutics, Inc. May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Join An Inquiry
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Violated Securities Laws And Investors Are Invited To Participate
Shareholders With Losses In Kyverna Therapeutics, Inc. Should Contact The Schall Law Firm About A Securities Fraud Investigation
Kyverna Therapeutics Inc May Have Violated Securities Regulations And The Schall Law Firm Invites Investors To Join An Inquiry
Shareholders In Kyverna Therapeutics, Inc. Are Urged To Partake In The Schall Law Firm's Securities Related Investigation
Source: https://incomestatements.info
Category: Stock Reports